Anus Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: ANS011 MIFTS: 55	Anus Cancer Categories: Cancer diseases, Gastrointestinal diseases, Immune diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Anus Cancer

MalaCards integrated aliases for Anus Cancer:

Name: Anus Cancer ¹¹ ¹⁴

Anal Cancer ¹¹ ¹⁹ ⁴¹ ⁷⁵

Malignant Neoplasm of Anus ⁷¹

Malignant Anal Tumor ¹¹

Cancer of the Anus ¹⁹

Anus Neoplasms ⁷¹

Anal Carcinoma ⁷¹

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Neoplasms

Malignant neoplasms of digestive organs

Malignant neoplasm of anus and anal canal

Malignant neoplasm: Anal canal

Malignant neoplasm: Anus, unspecified

External Ids:

Disease Ontology ¹¹ DOID:14110

ICD9CM ³⁴ 154.2 154.3

NCIt ⁴⁹ C7379

SNOMED-CT ⁶⁸ 93669004 93676009

ICD10 ³¹ C21.0 C21.1

UMLS ⁷¹ C0003463 C0153445 C0153446 more

Sources

Summaries for Anus Cancer

MedlinePlus: ⁴¹ The anus is where stool leaves your body when you go to the bathroom. It is made up of your outer layers of skin and the end of your large intestine. Anal cancer is a disease in which cancer cells form in the tissues of the anus. Anal cancer is rare. It is more common in smokers and people over 50. You are also at higher risk if you have HPV, have anal sex, or have many sexual partners. Symptoms include bleeding, pain, or lumps in the anal area. Anal itching and discharge can also be signs of anal cancer. Doctors use tests that examine the anus to diagnose anal cancer. They include a physical exam, endoscopy, ultrasound, and biopsy. Treatments include radiation therapy, chemotherapy, and surgery. NIH: National Cancer Institute

MalaCards based summary: Anus Cancer, also known as anal cancer, is related to human papillomavirus infectious disease and squamous cell carcinoma, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Anus Cancer is CD4 (CD4 Molecule), and among its related pathways/superpathways are Innate Immune System and Disease. The drugs Octreotide and Cemiplimab have been mentioned in the context of this disorder. Affiliated tissues include anus, lymph node and skin, and related phenotypes are Decreased viability and homeostasis/metabolism

GARD: ¹⁹ Anal cancer is a rare form of cancer that occurs due to abnormal and uncontrolled cell growth in the anus. Ssymptoms of the condition include rectal bleeding; a lump in or near the anus; anal pain; itching; changes in bowel habits; and/or swollen lymph nodes. In most cases, the underlying cause of Anal cancer is unknown. There appears to be a link between Anal cancer and the human papillomavirus (HPV) infection. Other risk factors for Anal cancer include HIV infection, sexual activity, smoking, and a weakened immune system.

Disease Ontology: ¹¹ A large intestine cancer that is located in the anus.

Wikipedia: ⁷⁵ Anal cancer is a cancer which arises from the anus, the distal opening of the gastrointestinal tract.... more...

Sources

Related Diseases for Anus Cancer

Diseases related to Anus Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 760)

#	Related Disease	Score	Top Affiliating Genes
1	human papillomavirus infectious disease	30.9	TP53 PIK3CA HRAS GP5 EGFR CTLA4
2	squamous cell carcinoma	30.9	TP53 PIK3CA KRT7 KRAS HRAS EGFR
3	papilloma	30.7	UBE3A TP53 KRT7 KRAS EGFR CDKN2A
4	syphilis	30.7	CD8A CD4 CCR6
5	crohn's disease	30.7	H2AC18 CD8A CD4 CCR6
6	rectum cancer	30.6	TP53 KRAS HRAS H2AC18 EGFR CCR6
7	rectal benign neoplasm	30.5	TP53 PIK3CA KRT7 KRAS HRAS EGFR
8	anal squamous cell carcinoma	30.5	ZNF582 WDR17 TP53 PIK3CA KRT7 H2AC18
9	immune deficiency disease	30.4	PDCD1 H2AC18 CTLA4 CD8A CD4 CCR6
10	basaloid squamous cell carcinoma	30.4	TP53 KRT7 CDKN2A
11	anal canal adenocarcinoma	30.4	KRT7 CAGE1
12	cervical cancer	30.3	UBE3A TP53 PIK3CA HRAS CDKN2A
13	anogenital venereal wart	30.3	UBE3A TP53 H2AC18 GP6 GP5 CDKN2A
14	deficiency anemia	30.2	TP53 H2AC18 CD8A CD4 CCR6
15	lymphatic system disease	30.2	TP53 H2AC18 CD8A CD4 CCR6
16	thrombocytopenia	30.2	PDCD1 GP6 GP5 CTLA4 CD4 CD274
17	adenocarcinoma	30.2	TP53 PIK3CA KRT7 KRAS HRAS EGFR
18	cellulitis	30.2	CD8A CD4 CCR6
19	suppressor of tumorigenicity 3	30.2	UBE3A TP53 CDKN2A
20	lymphoma	30.2	TP53 PDCD1 EGFR CDKN2A CD274 CCR6
21	telangiectasis	30.1	TP53 H2AC18 CCR6
22	urinary tract infection	30.1	H2AC18 CD4 CCR6
23	hepatitis a	30.1	PDCD1 CTLA4 CD4
24	appendiceal neoplasm	30.1	KRT7 KRAS HRAS
25	lymph node disease	30.1	H2AC18 CD8A CD4 CCR6
26	verrucous carcinoma	30.1	TP53 PIK3CA GP5 EGFR CDKN2A
27	penile benign neoplasm	30.0	TP53 PIK3CA GP5 CDKN2A CD274
28	basal cell carcinoma	30.0	TP53 KRT7 H2AC18 EGFR CDKN2A CCR6
29	appendix adenocarcinoma	30.0	TP53 KRT7 KRAS HRAS
30	adenosquamous carcinoma	29.9	KRT7 KRAS HRAS EGFR
31	vulva cancer	29.9	ZNF582 TP53 PIK3CA KRT7 HRAS GP5
32	lymphoma, non-hodgkin, familial	29.8	TP53 PIK3CA H2AC18 CTLA4 CD8A CD4
33	human immunodeficiency virus infectious disease	29.8	PDCD1 H2AC18 CD8A CD4 CCR6
34	mucinous adenocarcinoma	29.8	TP53 PIK3CA KRT7 KRAS HRAS EGFR
35	alcohol use disorder	29.8	H2AC18 CD4 CCR6
36	cervix uteri carcinoma in situ	29.8	ZNF582 TP53 GP6 GP5 CDKN2A CD4
37	toxic encephalopathy	29.7	TP53 H2AC18 CCR6
38	squamous cell carcinoma, head and neck	29.7	TP53 PIK3CA HRAS H2AC18 EGFR CDKN2A
39	viral infectious disease	29.6	PDCD1 H2AC18 CTLA4 CD4 CD274 CCR6
40	adenoid cystic carcinoma	29.6	TP53 PIK3CA KRT7 KRAS HRAS EGFR
41	myelodysplastic syndrome	29.5	TP53 KRAS HRAS H2AC18 CDKN2A CD8A
42	vaginal cancer	29.5	UBE3A TP53 KRT7 HRAS GP5 EGFR
43	endometrial cancer	29.4	TP53 PIK3CA KRT7 KRAS HRAS H2AC18
44	colorectal adenocarcinoma	29.3	TP53 PIK3CA KRT7 KRAS HRAS H2AC18
45	oropharynx cancer	29.3	UBE3A TP53 PIK3CA KRT7 HRAS H2AC18
46	penile cancer	29.2	UBE3A TP53 PIK3CA GP6 GP5 EGFR
47	gastrointestinal stromal tumor	29.2	TP53 PIK3CA KRAS HRAS H2AC18 EGFR
48	melanoma	29.2	TP53 PIK3CA PDCD1 KRAS HRAS CTLA4
49	colonic benign neoplasm	29.1	TP53 PIK3CA KRT7 KRAS HRAS H2AC18
50	peripheral nervous system disease	29.1	TP53 KRAS HRAS H2AC18 EGFR CTLA4

Comorbidity relations with Anus Cancer via Phenotypic Disease Network (PDN):

Acute Cystitis

Deficiency Anemia

Graphical network of the top 20 diseases related to Anus Cancer:

Sources

Symptoms & Phenotypes for Anus Cancer

UMLS symptoms related to Anus Cancer:

nausea and vomiting; constipation; abdominal pain; diarrhea; dyspepsia; icterus; heartburn; pruritus ani; gastrointestinal gas

GenomeRNAi Phenotypes related to Anus Cancer according to GeneCards Suite gene sharing:

²⁵ (show all 13)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-1	10.34	EGFR HRAS KRAS PIK3CA
2	Decreased viability	GR00055-A-2	10.34	EGFR HRAS KRAS PIK3CA
3	Decreased viability	GR00055-A-3	10.34	KRAS
4	Decreased viability	GR00106-A-0	10.34	KRAS
5	Decreased viability	GR00221-A-1	10.34	CDKN2A EGFR HRAS KRAS PIK3CA
6	Decreased viability	GR00221-A-2	10.34	HRAS KRAS PIK3CA
7	Decreased viability	GR00221-A-3	10.34	CDKN2A HRAS
8	Decreased viability	GR00221-A-4	10.34	CDKN2A EGFR PIK3CA
9	Decreased viability	GR00301-A	10.34	KRAS
10	Decreased viability	GR00381-A-1	10.34	KRAS
11	Decreased viability	GR00402-S-2	10.34	PIK3CA
12	no effect	GR00402-S-1	10.17	CAGE1 CCR6 CD274 CD4 CD8A CDKN2A
13	no effect	GR00402-S-2	10.17	CAGE1 CCR6 CD274 CD4 CDKN2A CTLA4

MGI Mouse Phenotypes related to Anus Cancer:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.24	CCR6 CD274 CD4 CDKN2A CTLA4 EGFR
2	no phenotypic analysis	MP:0003012	10.06	CD274 CD4 CDKN2A EGFR HRAS KRAS
3	endocrine/exocrine gland	MP:0005379	10.06	CD4 CD8A CDKN2A CTLA4 EGFR HRAS
4	neoplasm	MP:0002006	9.98	CDKN2A EGFR HRAS KRAS PDCD1 PIK3CA
5	immune system	MP:0005387	9.93	CCR6 CD274 CD4 CD8A CDKN2A CTLA4
6	digestive/alimentary	MP:0005381	9.86	CD4 CDKN2A CTLA4 EGFR HRAS KRAS
7	skeleton	MP:0005390	9.7	CD274 CDKN2A CTLA4 EGFR GP6 HRAS
8	integument	MP:0010771	9.4	CD274 CD4 CD8A CDKN2A CTLA4 EGFR

Sources

Drugs & Therapeutics for Anus Cancer

Drugs for Anus Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 113)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Octreotide

Approved, Investigational

Phase 3

83150-76-9

383414 6400441

Cemiplimab

Approved, Investigational

Phase 3

1801342-60-8

Atezolizumab

Approved, Investigational

Phase 3

1380723-44-3

Ipilimumab

Approved

Phase 3

477202-00-9

Calcium polycarbophil

Approved

Phase 3

126040-58-2

Imiquimod

Approved, Investigational

Phase 3

99011-02-6

57469

Capecitabine

Approved, Investigational

Phase 3

154361-50-9

60953

Paclitaxel

Approved, Vet_approved

Phase 3

33069-62-4

36314

Cisplatin

Approved

Phase 2, Phase 3

15663-27-1

2767 5702198 441203

Fluorouracil

Approved

Phase 2, Phase 3

51-21-8

3385

Mitomycin

Approved

Phase 2, Phase 3

50-07-7

5746

Immunosuppressive Agents

Phase 3

Alkylating Agents

Phase 3

Gastrointestinal Agents

Phase 3

Antineoplastic Agents, Hormonal

Phase 3

Psyllium

Phase 3

Immunologic Factors

Phase 3

Immune Checkpoint Inhibitors

Phase 3

Adjuvants, Immunologic

Phase 3

interferons

Phase 3

Anesthetics

Phase 3

Vaccines

Phase 3

Albumin-Bound Paclitaxel

Phase 3

Antimitotic Agents

Phase 3

Tubulin Modulators

Phase 3

Antimetabolites

Phase 2, Phase 3

Anti-Bacterial Agents

Phase 2, Phase 3

Antibiotics, Antitubercular

Phase 2, Phase 3

Formaldehyde

Approved, Vet_approved

Phase 2

50-00-0

712

Cidofovir

Approved

Phase 2

113852-37-2

60613

Panitumumab

Approved, Investigational

Phase 1, Phase 2

339177-26-3

Irinotecan

Approved, Investigational

Phase 1, Phase 2

97682-44-5, 100286-90-6

60838

Levoleucovorin

Approved, Experimental, Investigational

Phase 1, Phase 2

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Docetaxel

Approved, Investigational

Phase 2

114977-28-5

148124

Oxaliplatin

Approved, Investigational

Phase 2

61825-94-3

43805 11947679 6857599

Edetate calcium disodium anhydrous

Approved, Vet_approved

Phase 2

62-33-9, 60-00-4

6049

Pentetic acid

Approved

Phase 2

67-43-6

Valproic acid

Approved, Investigational

Phase 2

99-66-1

3121

Avelumab

Approved, Investigational

Phase 2

1537032-82-8

Niraparib

Approved, Investigational

Phase 1, Phase 2

1038915-60-4

24958200

Carboplatin

Approved

Phase 2

41575-94-4

10339178 38904

Durvalumab

Approved, Investigational

Phase 2

1428935-60-7

Vorinostat

Approved, Investigational

Phase 2

149647-78-9

5311

Pomalidomide

Approved

Phase 2

19171-19-8

134780

Thalidomide

Approved, Investigational, Withdrawn

Phase 2

50-35-1

5426

Cetuximab

Approved

Phase 2

205923-56-4

Palonosetron

Approved, Investigational

Phase 2

119904-90-4, 135729-56-5

148211 6337614

Manganese

Approved, Nutraceutical

Phase 1, Phase 2

7439-96-5

27854

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 1, Phase 2

59-30-3

6037

Entinostat

Investigational

Phase 1, Phase 2

209783-80-2

4261

Interventional clinical trials:

(show top 50) (show all 213)

#	Name	Status	NCT ID	Phase	Drugs
1	Randomized Trial to Evaluate Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy	Unknown status	NCT02369939	Phase 3	Mitomycin C;5-Fluorouracil
2	Second UK Phase III Anal Cancer Trial: A Trial of Chemoradiation and Maintenance Therapy for Patients With Anal Cancer	Completed	NCT00025090	Phase 3	cisplatin;fluorouracil;mitomycin C
3	A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of 9vHPV (V503), a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women	Completed	NCT01651949	Phase 3
4	Intensification Therapy for Locally Advanced Epidermoid Cancer of the Anal Canal - Phase III Intergroup Study	Completed	NCT00003652	Phase 3	cisplatin;fluorouracil
5	A Phase III Randomized Study of 5-Fluorouracil, Mitomycin-C, and Radiotherapy Versus 5-Fluorouracil, Cisplatin, and Radiotherapy in Carcinoma of the Anal Canal	Completed	NCT00003596	Phase 3	cisplatin;fluorouracil;mitomycin C
6	A Randomized, Double Blind, Placebo-Controlled Phase III Study To Determine The Efficacy Of Sandostatin LAR® Depot (Octreotide Acetate) In Preventing Or Reducing The Severity Of Chemoradiation-Induced Diarrhea In Patients With Anal Or Rectal Cancer	Completed	NCT00075868	Phase 3	octreotide acetate
7	A Randomized Clinical Trial of Infrared Coagulator (IRC) Ablation Versus Expectant Management of Intra-Anal High Grade Intraepithelial Neoplasia (HGAIN) in HIV-infected Adults	Completed	NCT01164722	Phase 3
8	A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Na�ve Metastatic Anal Cancer Patients	Recruiting	NCT04444921	Phase 3	Carboplatin;Paclitaxel
9	Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors	Recruiting	NCT04157985	Phase 3	Continue PD-1/PD-L1 Inhibitors treatment
10	A Phase 3, Multicenter, Double-Blind Randomized Study of Mitomycin, 5-Fluorouracil and IMRT Combined With or Without Anti-PD-1 in Patients With Locally Advanced Anal Canal Squamous Carcinoma	Recruiting	NCT05374252	Phase 3	PD-1 inhibitor
11	Reliability of Indocyanine Green Use in Sentinel Lymph Node Identification in Cancer Surgery	Recruiting	NCT02997553	Phase 3	Indocyanine green;Technetium99
12	Dietary Fiber During Radiotherapy and Intestinal Inflammation - a Placebo-controlled Randomized Trial (FIDURA)	Recruiting	NCT04534075	Phase 3
13	A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer	Active, not recruiting	NCT03233711	Phase 3
14	ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study	Active, not recruiting	NCT02135419	Phase 3	imiquimod;fluorouracil
15	A Phase 3, Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9vHPV Vaccine in Japanese Males, 16 to 26 Years of Age.	Active, not recruiting	NCT04635423	Phase 3
16	Randomised Phase III Trial of Chemoradiotherapy With or Without Paclitaxel in Patients With Squamous-cell Anal Cancer	Enrolling by invitation	NCT02526953	Phase 3	Paclitaxel;Capecitabine;Mitomycins
17	Continuous Fluorouracil Plus Mitomycin C Versus Mitomycin C Plus Cisplatin As Chemotherapy Combination In Combined Radiochemotherapy For Locally Advanced Anal Cancer. A Phase II-III Study	Terminated	NCT00068744	Phase 2, Phase 3	cisplatin;fluorouracil;mitomycin C
18	An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel in Patients With Inoperable Locally Recurrent or Metastatic Disease	Unknown status	NCT02051868	Phase 2	Cisplatin;5-Fluorouracil (5-FU);Carboplatin;Paclitaxel
19	Phase II Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer	Unknown status	NCT03381352	Phase 2	Capecitabine;Mitomycin C
20	A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand	Unknown status	NCT03302858	Phase 2
21	Randomized Phase 2 Trial of Cetuximab and Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment	Unknown status	NCT03944252	Phase 2	Avelumab;Cetuximab
22	Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: A Prospective, Phase II Trial Assessing Acute Toxicities Rates Compared to Historic Controls Treated With Volumetric Modulated Arc Therapy (VMAT)	Completed	NCT03690921	Phase 2	Cisplatin;Fluorouracil
23	A Phase II Evaluation of Dose-Painted Intensity-Modulated Radiation Therapy (IMRT) in Combination With 5-Fluorouracil (5-FU) and Mitomycin-C for Reduction of Acute Morbidity in Carcinoma of the Anal Canal	Completed	NCT00423293	Phase 2	fluorouracil;mitomycin C
24	A Phase I/II Study of T Cell Receptor Gene Therapy Targeting HPV-16 E6 for HPV-Associated Cancers	Completed	NCT02280811	Phase 1, Phase 2	Fludarabine;Cyclophosphamide;Aldesleukin
25	Phase IIA Trial of 1% Topical Cidofovir for Treatment of High-Grade Perianal Squamous Intraepithelial Lesions in HIV-Infected Men and Women	Completed	NCT00550589	Phase 2	cidofovir
26	A Phase II Study of Capecitabine (Xeloda)/Oxaliplatin (Eloxatin) With Concomitant Radiotherapy (XRT), XELOX/RT in Squamous Cell Carcinoma of the Anal Canal	Completed	NCT00093379	Phase 2	Capecitabine;Oxaliplatin
27	A Phase I/II Trial of SGN-00101 in the Treatment of High-Grade Anal Intraepithelial Neoplasia (AIN) in HIV-Positive Individuals	Completed	NCT00052897	Phase 1, Phase 2
28	Phase 2 Study of ADXS11-001 in Subjects With Persistent/Recurrent, Loco-Regional or Metastatic Squamous Cell Carcinoma of the Anorectal Canal	Completed	NCT02399813	Phase 2	ADXS11-001
29	Phase II Trial of Combined Modality Therapy Plus Cetuximab in HIV-Associated Anal Carcinoma	Completed	NCT00324415	Phase 2	cisplatin;fluorouracil
30	Phase II Trial of Cetuximab Plus Cisplatin, 5- Fluorouracil and Radiation in Immunocompetent Patients With Anal Carcinoma	Completed	NCT00316888	Phase 2	cisplatin;fluorouracil
31	A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers	Completed	NCT01585428	Phase 2	Fludarabine;Cyclophosphamide;Aldesleukin
32	AMC-072: Protective Effect of Quadrivalent Vaccine in Young HIV-Positive Males Who Have Sex With Males	Completed	NCT01209325	Phase 2
33	A Phase II, Prospective, Open-label, Pilot Study of the Tolerability, Safety, and Efficacy of Argon Plasma Coagulation for the Treatment of Anal Intraepithelial Neoplasia Grade 2 or 3 in HIV-positive Men Having Sex With Men	Completed	NCT00428285	Phase 2
34	Phase II Study for Treatment of Anal HSIL Through Use of a Chinese Herbal Topical Cream	Completed	NCT00622440	Phase 2	AIJP (Arnebia Indigo Jade Pearl);Placebo
35	Improving Pelvic Cancer Patient Chemoradiotherapy Outcomes With FLT PET Imaging	Completed	NCT01717391	Phase 2	fluorothymidine F 18
36	Assessment of the Clinical Value of a Docetaxel, Cisplatin and 5-fluorouracil (DCF) Strategy Adapted to Patients for the Management of Metastatic or Locally Advanced Anal Resistant Radiochemotherapy Squamous Cell Anal Carcinoma.	Completed	NCT02402842	Phase 2	Docetaxel, Cisplatin and 5-Fluorouracil
37	Phase I-II on Radiochemotherapy Combined With Panitumumab in the Treatment of Localised Epidermoid Carcinoma of the Anus	Completed	NCT01581840	Phase 1, Phase 2	radiochemotherapy;Panitumumab
38	A Phase 2, Open Label, Study of VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL), (AIN2, AIN3, PAIN2, PAIN3) in Individuals That Are Seronegative for Human Immunodeficiency Virus (HIV)-1/2	Completed	NCT03499795	Phase 2
39	Phase 2 Trial to Assess the Efficacy and Safety of Chemoradiation With 5-fluorouracil, Mytomicin C and Panitumumab as a Treatment for Anal Squamous Cell Carcinoma	Completed	NCT01285778	Phase 2	panitumumab, mytomicin C, 5-FU, radiation
40	Risk-Adapted Therapy for HIV-Associated Anal Cancer	Recruiting	NCT04929028	Phase 2	Capecitabine;Fluorouracil;Mitomycin
41	Randomized Controlled Trial of Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes	Recruiting	NCT04907643	Phase 2
42	Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma.	Recruiting	NCT04230759	Phase 2	Chemotherapy;Durvalumab
43	ReRad III. Pencil Beam Proton Therapy for Recurrences in Anal Cancer Patients Previously Treated With Radiotherapy	Recruiting	NCT05055635	Phase 2
44	A Randomized Phase II Study De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)	Recruiting	NCT04166318	Phase 2	Capecitabine;Fluorouracil;Mitomycin
45	A Phase 1 Trial for Patients With Newly Diagnosed Anal Cancer Treated With Concurrent Radiation Therapy, 5FU, Mitomycin and BMX-001	Recruiting	NCT03386500	Phase 1, Phase 2	BMX-001
46	ROAR-A: Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer	Recruiting	NCT05438836	Phase 2
47	A Randomized Phase II Study of the Administration of Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy for Patients With Squamous Cell Carcinoma of the Anal Canal (BISQUIT)	Recruiting	NCT03870607	Phase 2
48	Phase I/II Trial of Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies	Recruiting	NCT04287868	Phase 1, Phase 2
49	A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers	Recruiting	NCT04708470	Phase 1, Phase 2	Bintrafusp Alfa;NHS-IL12;Entinostat
50	A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)	Recruiting	NCT02628067	Phase 2

Search NIH Clinical Center for Anus Cancer

Sources

Genetic Tests for Anus Cancer

Sources

Anatomical Context for Anus Cancer

Organs/tissues related to Anus Cancer:

FMA: Anus

MalaCards : Lymph Node, Skin, T Cells, Cervix, Colon, Prostate, Lung

Sources

Publications for Anus Cancer

Articles related to Anus Cancer:

(show top 50) (show all 2652)

#	Title	Authors	PMID	Year
1	Influence of radiation treatment technique (IMRT vs. 3D-RT) on acute toxicity and prognostic factors for survival for anal cancer. ⁶² ⁴¹	Sauter C...Dapper H	36402828	2022
2	"The problem is that our culture is just so messed up about aging." Recruiting older men who have sex with men (MSM) into research studies: an example from a study of aging, HIV, and anal HPV. ⁶² ⁴¹	Hernandez AL...Palefsky JM	36401159	2022
3	Workplace violence at emergency departments, Ain Shams University Hospitals, Cairo, Egypt. ⁴¹	Assil AO...Azab SMS	36443795	2022
4	Anal Cancer Prevention Through the Topical Use of Single or Dual PI3K/mTOR Inhibitors. ⁶²	Gunder LC...Carchman EH	36274448	2023
5	Prostrate After Prostate? Recommend Attempt for Definitive Treatment of Oligometastatic Anal Cancer After Low Dose Rate Brachytherapy. ⁶²	Aliru ML...Sanford NN	36395800	2022
6	Sowing the Seeds: A Case of Oligometastatic Anal Cancer 12 Years After Prostate Brachytherapy. ⁶²	Tchelebi LT	36395797	2022
7	Use of the Toxicity Index in Evaluating Adverse Events in Anal Cancer Trials: Analysis of RTOG 9811 and RTOG 0529. ⁶²	Kharofa JR...Crane CH	36413683	2022
8	Effect of the environment on home-based self-sampling kits for anal cancer screening. ⁶²	Nitkowski J...Nyitray AG	36096333	2022
9	Assessment of Patient-Reported Outcomes in Patients With Anal Squamous-Cell Cancer Undergoing Combined Modality Therapy. ⁶²	Taylor JP...Pappou E	36102865	2022
10	A Cross-Sectional Study of the Prevalence of Anal Dysplasia among Women with High-Grade Cervical, Vaginal, and Vulvar Dysplasia or Cancer: The PANDA Study. ⁶²	Batman S...Schmeler KM	36126275	2022
11	HPV-Associated Anal Cancer Knowledge, Attitudes, and Health Communication Behaviors Among Non-clinical Providers at HIV/AIDS Service Organizations in Southern United States Region. ⁶²	Olusanya OA...Wigfall LT	34148218	2022
12	A systematic review and meta-analysis of cytology and HPV-related biomarkers for anal cancer screening among different risk groups. ⁶²	Clarke MA...Wentzensen N	35793241	2022
13	A pilot study investigating the role of 18 F-FDG-PET in the early identification of chemoradiotherapy response in anal cancer. ⁶²	Smith D...Khoo V	35906833	2022
14	Comparison of four assays for human papillomavirus detection in the anal canal. ⁶²	Poynten IM...Study of Prevention of Anal Cancer Study Team	35809783	2022
15	Artificial intelligence and high-resolution anoscopy: automatic identification of anal squamous cell carcinoma precursors using a convolutional neural network. ⁶²	Saraiva MM...de Parades V	35986806	2022
16	Identifying Predictors of Anal HPV Status in HPV-Vaccinated MSM: A Machine Learning Approach. ⁶²	Ocagli H...Clemente L	36332152	2022
17	Radiological incidence of donor-site incisional hernia and parastomal hernia after vertical rectus abdominus myocutaneous flap-based reconstruction following colorectal surgery. ⁶²	Tang AM...Harries RL	36328985	2022
18	Prevalence and Predictors of High-Grade Anal Dysplasia in People With HIV in One Southeastern Ryan White HIV/AIDS Program Clinic. ⁶²	Geba M...Thomas TA	36467302	2022
19	Evaluation of dosimetric predictors of toxicity after IMRT with concurrent chemotherapy for anal cancer. ⁶²	Lukovic J...Kim JJ	36455685	2022
20	Successful Management of Anal Squamous Cell Carcinoma With Liver and Ovary Metastases: A Case Report. ⁶²	Mitsuura C...Baba H	36309369	2022
21	Conventional cytologic diagnosis of human papillomavirus-induced anal intraepithelial neoplasia: The experience of a referral center in Rio de Janeiro, Brazil. ⁶²	de Barcellos LP...Russomano FB	36398627	2022
22	International validation of the EORTC QLQ-ANL27, a field study to test the anal cancer-specific health-related quality of life questionnaire. ⁶²	Sodergren SC...EORTC Quality of Life Group	36402360	2022
23	The effect of recombinant human epidermal growth factor on radiation dermatitis in rectal and anal cancer patients: a self-controlled study. ⁶²	Liu S...Liu YP	36335306	2022
24	Overview of Radiation Treatment Volume Variations in Anal Cancer Contouring Guidelines. ⁶²	Rudra S	35718076	2022
25	Challenges and controversies patients and (health care) professionals experience in managing vaginal, vulvar, penile or anal cancer: The SILENCE study. ⁶²	van Dongen J...Duijts SFA	35938519	2022
26	Online adaptive radiotherapy of anal cancer: Normal tissue sparing, target propagation methods, and first clinical experience. ⁶²	Astrom LM...Serup-Hansen E	36174846	2022
27	One-Drop Serum Screening Test for Anal Cancer in Men via Infrared Attenuated Total Reflection Spectroscopy. ⁶²	Alcantara-Quintana LE...Diaz de Leon-Martinez L	36197692	2022
28	Patients with Anal Cancer Have Low Functional and High Symptomatic Health-Related Quality of Life Scores After Chemoradiation. ⁶²	Ginesi M...Steinhagen E	36369421	2022
29	HPV status and HPV16 viral load in anal cancer and its association with clinical outcome. ⁶²	Guerendiain D...Cuschieri K	35785486	2022
30	ASO Visual Abstract: Intraoperative Radiation Therapy for Colorectal or Anal Cancer at Risk for Margin-Positive Resection: Initial Results of a Single-Institution Registry. ⁶²	Arshad M...Liauw SL	36224512	2022
31	Prevention of human papillomavirus-related anal cancer in women living with human immunodeficiency virus. ⁶²	Clifford GM...Wei F	36196561	2022
32	Intra-operative Radiation Therapy for Colorectal or Anal Cancer at Risk for Margin-Positive Resection: Initial Results of a Single-Institution Registry. ⁶²	Arshad M...Liauw SL	36255512	2022
33	[Anal cancer: Focus on current treatment and future perspective]. ⁶²	Delhiat AC...Vendrely V	36008262	2022
34	High dose rate brachytherapy for anal cancer: A review of a systematic review. ⁶²	Chow R...Simone CB	35964764	2022
35	External validation of a composite bio-humoral index in anal cancer patients undergoing concurrent chemoradiation. ⁶²	Franco P...Caravatta L	36273737	2022
36	Primary Anal Cancer Screening Results from 381 Women Living with Human Immunodeficiency Virus. ⁶²	Liu Y...Sigel K	36196502	2022
37	Linguistic validation of the Spanish version of the Anal Cancer High-Grade squamous intraepithelial lesions outcomes Research Health-Related Symptom Index (A-HRSI): AMC-A04. ⁶²	Atkinson TM...Palefsky JM	36219358	2022
38	The emerging role of immunotherapy in the treatment of anal cancer. ⁶²	Saude-Conde R...Sclafani F	36334330	2022
39	Automated Evaluation of p16/Ki-67 Dual-Stain Cytology as a Biomarker for Detection of Anal Precancer in Men Who Have Sex With Men and Are Living With Human Immunodeficiency Virus. ⁶²	Cohen CM...Clarke MA	35325073	2022
40	Concurrent Chemo-radiotherapy in Anal Squamous Cell Carcinoma: A Retrospective Review of a Tertiary Centre Experience. ⁶²	Patel C...Giridharan S	36269537	2022
41	CROI 2022: tuberculosis and infectious complications in persons With HIV. ⁶²	Kerkhoff AD...Havlir DV	36347059	2022
42	A nationwide longitudinal study on risk factors for progression of anal intraepithelial neoplasia grade 3 to anal cancer. ⁶²	Faber MT...Kjaer SK	35657350	2022
43	Incidence and mortality of non-AIDS-defining cancers among people living with HIV: A systematic review and meta-analysis. ⁶²	Yuan T...Zou H	35990580	2022
44	CROI 2022: metabolic and other complications of HIV infection or COVID-19. ⁶²	Sarkar S...Brown TT	36347058	2022
45	Update to the structured MRI report for primary staging of rectal cancer : Perspective from the SAR Disease Focused Panel on Rectal and Anal Cancer. ⁶²	Kassam Z...Kim DH	35881198	2022
46	Concurrent anorectal and cervical cytology in women with positive and negative cervical smear test results: A cross-sectional study. ⁶²	Tehranian A...Aghajani R	36183298	2022
47	[Human Papillomavirus: screening of cervical and anal cancers]. ⁶²	Pache B...Mathevet P	36259700	2022
48	Cytology and LGBT+ health: establishing inclusive cancer screening programs. ⁶²	Compton ML...Ely KA	35840516	2022
49	"Global Multidisciplinary Team Meetings": Challenging Cases Virtual Forums from the International Multidisciplinary Anal Cancer Conference (IMACC). ⁶²	Segelov E...Spindler KG	35346604	2022
50	Evaluating the cascade of care for anal cancer screening within a Ryan White HIV/AIDS Program clinic. ⁶²	Cardenas BF...Thomas TA	35833535	2022

Sources

Genes for Anus Cancer

Genes related to Anus Cancer (0 elite genes):

(show all 27)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	CD4	CD4 Molecule	Protein Coding	7.27	DISEASES inferred ¹⁴
2	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	7.02	DISEASES inferred ¹⁴
3	H2AC18	H2A Clustered Histone 18	Protein Coding	6.51	DISEASES inferred ¹⁴ ¹⁴
4	TP53	Tumor Protein P53	Protein Coding	6.46	DISEASES inferred ¹⁴
5	GP5	Glycoprotein V Platelet	Protein Coding	6.32	DISEASES inferred ¹⁴
6	CD274	CD274 Molecule	Protein Coding	6.31	DISEASES inferred ¹⁴
7	CD8A	CD8a Molecule	Protein Coding	6.13	DISEASES inferred ¹⁴
8	EGFR	Epidermal Growth Factor Receptor	Protein Coding	5.96	DISEASES inferred ¹⁴
9	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	5.83	DISEASES inferred ¹⁴
10	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	5.81	DISEASES inferred ¹⁴
11	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	5.77	DISEASES inferred ¹⁴ ¹⁴
12	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	5.66	DISEASES inferred ¹⁴
13	UBE3A	Ubiquitin Protein Ligase E3A	Protein Coding	5.65	DISEASES inferred ¹⁴
14	ZNF582	Zinc Finger Protein 582	Protein Coding	5.59	DISEASES inferred ¹⁴
15	CAGE1	Cancer Antigen 1	Protein Coding	5.58	DISEASES inferred ¹⁴
16	KRT7	Keratin 7	Protein Coding	5.53	DISEASES inferred ¹⁴
17	GP6	Glycoprotein VI Platelet	Protein Coding	5.52	DISEASES inferred ¹⁴
18	CTLA4	Cytotoxic T-Lymphocyte Associated Protein 4	Protein Coding	5.51	DISEASES inferred ¹⁴
19	WDR17	WD Repeat Domain 17	Protein Coding	5.42	DISEASES inferred ¹⁴
20	PDCD1	Programmed Cell Death 1	Protein Coding	5.33	DISEASES inferred ¹⁴
21	CEACAM5	CEA Cell Adhesion Molecule 5	Protein Coding	5.32	DISEASES inferred ¹⁴
22	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	5.25	DISEASES inferred ¹⁴
23	RB1	RB Transcriptional Corepressor 1	Protein Coding	5.19	DISEASES inferred ¹⁴
24	MCM7	Minichromosome Maintenance Complex Component 7	Protein Coding	5.17	DISEASES inferred ¹⁴
25	IL2	Interleukin 2	Protein Coding	5.13	DISEASES inferred ¹⁴
26	CDX2	Caudal Type Homeobox 2	Protein Coding	5.11	DISEASES inferred ¹⁴
27	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	5.1	DISEASES inferred ¹⁴

Sources

Variations for Anus Cancer

Sources

Expression for Anus Cancer

Search GEO for disease gene expression data for Anus Cancer.

Sources

Pathways for Anus Cancer

Pathways related to Anus Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 59)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	13.97	UBE3A TP53 PIK3CA PDCD1 KRAS HRAS
2	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.79	TP53 PIK3CA PDCD1 KRAS HRAS H2AC18
3	Class I MHC mediated antigen processing and presentation ⁶⁶ Show member pathways Adaptive Immune System ⁶⁶ Antigen processing: Ubiquitination and Proteasome degradation ⁶⁶ Neddylation ⁶⁶	13.43	UBE3A PIK3CA PDCD1 KRAS HRAS CTLA4
4	TNFR1 Pathway ⁶⁴ Show member pathways Apoptosis ⁷⁴ Apoptosis and survival TNFR1 signaling pathway ²² Apoptosis modulation by HSP70 ⁷⁴ Apoptosis through Death Receptors ⁶⁴ Apoptotic Pathways Triggered By HIV1 ⁶⁴ Ceramide signaling pathway ⁶¹ DR3 Signaling ⁶⁴ GITR Pathway ⁶⁴ HIV-1 Nef: Negative effector of Fas and TNF-alpha ⁶¹ Stimulation of the cell death response by PAK-2p34 ⁶⁶ TNF Signaling ⁶⁴ TNF-related weak inducer of apoptosis (TWEAK) signaling pathway ⁷⁴ TRAIL Pathway ⁶⁴ TWEAK Pathway ⁶⁴	12.92	TP53 PIK3CA HRAS EGFR CDKN2A CD4
5	TCR Signaling (Qiagen) ⁶⁴ Show member pathways Fc-EpsilonRI Pathway ⁶⁴ ITK and TCR Signaling ⁶⁴ PDGF Pathway ⁶⁴ PKC-Theta Pathway ⁶⁴	12.91	TP53 KRAS HRAS CTLA4 CD8A CD4
6	CCR5 Pathway in Macrophages ⁶⁴ Show member pathways Androgen Signaling ⁶⁴ Chemokine Signaling ⁶⁴ Chemokine signaling pathway ⁷⁴	12.86	PIK3CA KRAS HRAS CD4 CCR6
7	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.84	PIK3CA KRAS HRAS EGFR CD274
8	4-1BB Pathway ⁶⁴ Show member pathways CD27 Pathway ⁶⁴ CD40 Signaling ⁶⁴ CMV and MAPK Pathways ⁶⁴ NF-KappaB Activation by EBV ⁶⁴ NF-kappaB Activation by Viruses ⁶⁴ PKR Pathway ⁶⁴ SUMO Pathway ⁶⁴ TNFR2 Pathway ⁶⁴	12.66	CD4 EGFR HRAS KRAS TP53
9	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.55	TP53 PIK3CA KRAS HRAS EGFR CDKN2A
10	Malignant pleural mesothelioma ⁷⁴	12.49	TP53 PIK3CA HRAS EGFR CDKN2A CD274
11	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.42	TP53 PIK3CA KRAS HRAS EGFR
12	Development Dopamine D2 receptor transactivation of EGFR ²² Show member pathways Chemotaxis CXCR4 signaling pathway ²² Development Alpha-2 adrenergic receptor activation of ERK ²² Extra-nuclear estrogen signaling ⁶⁶	12.41	PIK3CA KRAS HRAS EGFR
13	MAPK signaling pathway ⁷⁴	12.4	EGFR HRAS KRAS TP53
14	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.38	CD4 EGFR HRAS KRAS PIK3CA TP53
15	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.37	TP53 PIK3CA KRAS HRAS EGFR
16	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.36	TP53 PIK3CA KRAS HRAS EGFR
17	B Cell Receptor Signaling Pathway ⁶⁷ Show member pathways T Cell Receptor Signaling Pathway ⁶⁷	12.32	PIK3CA KRAS HRAS CD4
18	Ras signaling ⁷⁴	12.25	EGFR HRAS KRAS PIK3CA
19	Signaling by ERBB2 KD Mutants ⁶⁶ Show member pathways Constitutive Signaling by Overexpressed ERBB2 ⁶⁶ GRB2 events in ERBB2 signaling ⁶⁶ PI3K events in ERBB2 signaling ⁶⁶ PI3K events in ERBB4 signaling ⁶⁶ PLCG1 events in ERBB2 signaling ⁶⁶ SHC1 events in ERBB2 signaling ⁶⁶ SHC1 events in ERBB4 signaling ⁶⁶ Signaling by ERBB2 ECD mutants ⁶⁶ Signaling by ERBB2 in Cancer ⁶⁶ Signaling by ERBB2 TMD/JMD mutants ⁶⁶	12.24	PIK3CA KRAS HRAS EGFR
20	Cell surface interactions at the vascular wall ⁶⁶ Show member pathways Fibronectin matrix formation ⁶⁶ PECAM1 interactions ⁶⁶ Tie2 Signaling ⁶⁶	12.21	PIK3CA KRAS HRAS GP6
21	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.19	TP53 PIK3CA KRAS HRAS EGFR
22	Epithelial to mesenchymal transition in colorectal cancer ⁷⁴	12.17	TP53 PIK3CA KRAS HRAS
23	CD28 co-stimulation ⁶⁶ Show member pathways Activation of AKT2 ⁶⁶ CD28 dependent PI3K/Akt signaling ⁶⁶ CD28 dependent Vav1 pathway ⁶⁶ Costimulation by the CD28 family ⁶⁶ CTLA4 Signaling ⁶⁴ VEGFR2 mediated vascular permeability ⁶⁶	12.11	PIK3CA PDCD1 CTLA4 CD8A CD4 CD274
24	Signaling by EGFR in Cancer ⁶⁶ Show member pathways Constitutive Signaling by EGFRvIII ⁶⁶ Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants ⁶⁶ EGFR interacts with phospholipase C-gamma ⁶⁶ EGFR-dependent Endothelin signaling events ⁶¹ GRB2 events in EGFR signaling ⁶⁶ SHC1 events in EGFR signaling ⁶⁶ Signaling by EGFRvIII in Cancer ⁶⁶ Signaling by Ligand-Responsive EGFR Variants in Cancer ⁶⁶	12.08	EGFR HRAS KRAS PIK3CA
25	Signaling by ERBB4 ⁶⁶ Show member pathways Downregulation of ERBB4 signaling ⁶⁶ ErbB4 signaling events ⁶¹ Nuclear signaling by ERBB4 ⁶⁶	12.06	PIK3CA KRAS HRAS EGFR
26	Signaling by ERBB2 ⁶⁶ Show member pathways Downregulation of ERBB2 signaling ⁶⁶ Downregulation of ERBB2:ERBB3 signaling ⁶⁶ ERBB2 Activates PTK6 Signaling ⁶⁶ ERBB2 Regulates Cell Motility ⁶⁶ GRB7 events in ERBB2 signaling ⁶⁶	12.03	PIK3CA KRAS HRAS EGFR
27	Development EGFR signaling via small GTPases ²² Show member pathways Development EGFR signaling via PIP3 ²² Development PDGF signaling via MAPK cascades ²²	11.96	PIK3CA KRAS HRAS EGFR
28	Signaling by PDGF ⁶⁶ Show member pathways Downstream signal transduction ⁶⁶	11.84	PIK3CA KRAS HRAS
29	DNA damage response (only ATM dependent) ⁷⁴	11.83	TP53 PIK3CA KRAS HRAS
30	Thyroid hormones production and peripheral downstream signaling effects ⁷⁴	11.82	TP53 PIK3CA HRAS
31	Innate Lymphoid Cells Differentiation ⁶⁵	11.8	CD8A CD4 CCR6
32	Signaling by EGFR ⁶⁶ Show member pathways EGFR downregulation ⁶⁶ GAB1 signalosome ⁶⁶	11.8	EGFR HRAS KRAS PIK3CA
33	VEGF Pathway (Tocris) ⁷⁰ Show member pathways Sorafenib Pharmacodynamics ⁶⁰	11.79	PIK3CA KRAS HRAS
34	Phosphorylation of CD3 and TCR zeta chains ⁶⁶ Show member pathways Generation of second messenger molecules ⁶⁶ PD-1 signaling ⁶⁶	11.78	PDCD1 CD4 CD274
35	Gastrin signaling pathway ⁷⁴	11.77	PIK3CA KRAS HRAS EGFR CDKN2A
36	DAP12 interactions ⁶⁶ Show member pathways DAP12 signaling ⁶⁶	11.76	PIK3CA KRAS HRAS
37	Pathways affected in adenoid cystic carcinoma ⁷⁴	11.67	TP53 PIK3CA HRAS
38	Serotonin HTR1 group and FOS pathway ⁷⁴ Show member pathways Serotonin receptor 2 and ELK-SRF/GATA4 signaling ⁷⁴ Serotonin receptor 4/6/7 and NR3C signaling ⁷⁴	11.66	PIK3CA KRAS HRAS
39	Prader-Willi and Angelman syndrome ⁷⁴	11.65	UBE3A TP53 CDKN2A
40	BDNF-TrkB signaling ⁷⁴ Show member pathways Synaptic signaling pathways associated with autism spectrum disorder ⁷⁴	11.65	UBE3A KRAS HRAS
41	mTOR Pathway ⁷⁰ Show member pathways TGF-beta Pathway ⁷⁰	11.63	TP53 PIK3CA KRAS HRAS
42	Agrin Interactions at Neuromuscular Junction ⁶⁴	11.62	KRAS HRAS EGFR
43	Signaling by PDGFR in disease ⁶⁶ Show member pathways Signaling by cytosolic PDGFRA and PDGFRB fusion proteins ⁶⁶ Signaling by membrane-tethered fusions of PDGFRA or PDGFRB ⁶⁶ Signaling by PDGFRA extracellular domain mutants ⁶⁶ Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants ⁶⁶	11.57	PIK3CA KRAS HRAS
44	Interactions between immune cells and microRNAs in tumor microenvironment ⁷⁴	11.53	PDCD1 CTLA4 CD274
45	Vemurafenib Pathway, Pharmacodynamics ⁶⁰	11.47	KRAS HRAS EGFR
46	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	11.41	TP53 PIK3CA PDCD1 HRAS CTLA4 CDKN2A
47	Kisspeptin/kisspeptin receptor system in the ovary ⁷⁴	11.4	PIK3CA KRAS HRAS
48	a6b1 and a6b4 Integrin signaling ⁶¹	11.39	PIK3CA HRAS EGFR
49	Head and neck squamous cell carcinoma ⁷⁴	11.3	TP53 PIK3CA KRAS HRAS EGFR CDKN2A
50	PI3K-AKT-mTOR signaling pathway and therapeutic opportunities ⁷⁴	11.28	PIK3CA KRAS HRAS